NCT02879513.

Study name	Trial of adjuvant chemotherapy in breast cancer patients with pathological partial response and complete response to neoadjuvant chemotherapy
Methods	Accrual: recruiting Accrual target: 290 Single or multicentre, phase 3 RCT Trial is being conducted in China Blinding: open‐label study
Participants	People with locally advanced breast cancer and had weekly paclitaxel and cisplatin as neoadjuvant chemotherapy Adjuvant or neoadjuvant: adjuvant
Interventions	Arm 1: intervention 1 and 2 ('continue neoadjuvant regimen' and 'pathological complete response group with chemotherapy in trial record): paclitaxel 80 mg/m2 on days 1 and 8 for 16 weeks, followed by cisplatin 25 mg/m2 weekly on days 1, 8 and 15, every 4 weeks for 4 cycles Arm 2: comparator: epirubicin 75 mg/m2 on day 1 every 3 weeks for 4 cycles, cyclophosphamide 500 mg/m2 on day 1 every 3 weeks and 5‐fluorouracil 500 mg/m2 on day 1 every 3 weeks
Outcomes	Primary Disease‐free survival Second Overall survival Treatment‐related adverse events Regional recurrence‐free survival Local recurrence‐free survival Distant disease‐free survival
Starting date	Planned start date: January 2014 Estimated completion date: December 2022
Contact information	Contact: Jinsong Lu (lujjss@163.com)
Notes	Trial registration link: clinicaltrials.gov/ct2/show/NCT02879513 Trial sponsor: RenJi Hospital Funding considerations: not specified in trial record